AstraZeneca’s Lynparza Adds Narrow Prostate Cancer Indication

FDA Follows Advisory Panel Recommendation On PARP Inhibitor

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.